Contrasting Dicerna Pharmaceuticals (NASDAQ:DRNA) & Clovis Oncology (CLVS)

Share on StockTwits

Clovis Oncology (NASDAQ:CLVS) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Volatility and Risk

Clovis Oncology has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.

Profitability

This table compares Clovis Oncology and Dicerna Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clovis Oncology -390.65% -108.92% -40.59%
Dicerna Pharmaceuticals -1,418.01% -63.24% -51.85%

Institutional and Insider Ownership

74.5% of Dicerna Pharmaceuticals shares are held by institutional investors. 10.2% of Clovis Oncology shares are held by insiders. Comparatively, 19.9% of Dicerna Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Clovis Oncology and Dicerna Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clovis Oncology $55.51 million 14.86 -$346.39 million ($5.12) -3.06
Dicerna Pharmaceuticals $2.28 million 404.99 -$60.04 million ($3.66) -4.02

Dicerna Pharmaceuticals has lower revenue, but higher earnings than Clovis Oncology. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Clovis Oncology and Dicerna Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clovis Oncology 0 5 9 0 2.64
Dicerna Pharmaceuticals 0 1 7 0 2.88

Clovis Oncology presently has a consensus price target of $57.05, suggesting a potential upside of 264.55%. Dicerna Pharmaceuticals has a consensus price target of $20.93, suggesting a potential upside of 42.18%. Given Clovis Oncology’s higher probable upside, equities research analysts plainly believe Clovis Oncology is more favorable than Dicerna Pharmaceuticals.

Summary

Dicerna Pharmaceuticals beats Clovis Oncology on 8 of the 13 factors compared between the two stocks.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.